NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

Your main premise for your agreement is not true:

Only the NWBO's SEC filing on 3/31/21 finally reported reported the PFS confounding.

You should read the DCVAX unblinded journal article May 2018
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

The study’s primary endpoint is PFS, and the secondary endpoint is OS. PFS has not yet been evaluated for this publication and will be the subject of later analyses to allow for central, multi-factorial assessment by an expert panel, using criteria currently emerging as appropriate for immune therapy in this patient population where progression can be complex to determine and pseudo-progression is a known confounding phenomenon.

PFS Confounding is clearly noted as an issue.